{"id":2911,"date":"2026-05-08T17:32:00","date_gmt":"2026-05-08T15:32:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=9c2ecf5b8a0b4a78c0ba46b893ded5ec"},"modified":"2026-05-08T17:32:00","modified_gmt":"2026-05-08T15:32:00","slug":"niagen-bioscience-announces-participation-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=2911","title":{"rendered":"Niagen Bioscience Announces Participation in Upcoming Investor Conferences"},"content":{"rendered":"<p>LOS ANGELES--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/search?q=%24NAGE&src=ctag\" >$NAGE<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/Biotech?src=hash\" >#Biotech<\/a>--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=d56ea3f5b36913893cc998a98b86c89e\" rel=\"nofollow\" shape=\"rect\">Niagen Bioscience, Inc.<\/a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences:<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260508658207\/en\/2414362\/5\/Niagen_Bioscience_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260508658207\/en\/2414362\/22\/Niagen_Bioscience_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260508658207\/en\/2414362\/5\/Niagen_Bioscience_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260508658207\/en\/2414362\/21\/Niagen_Bioscience_Logo.jpg\" \/><\/a><p>\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sohnconference.org%2Fsohn2026&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=31st+Annual+Sohn+Investment+Conference&amp;index=2&amp;md5=27e76fa5caee2cee299746c90f0e0006\" rel=\"nofollow\" shape=\"rect\">31st Annual Sohn Investment Conference<\/a><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Location<\/b>: Jazz at Lincoln Center\u2019s Frederick P. Rose Hall<\/li>\n<li>\n<b>Date<\/b>: May 12, 2026<\/li>\n<li>\n<b>Format<\/b>: Emerging Company Pavilion, a curated showcase of 8-10 select companies<\/li>\n<li>\n<b>Management<\/b>: Ozan Pamir, CFO<\/li>\n<\/ul><p>\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.benchmarkcompany.com%2F4th-annual-consumer-one-on-one-conference-2%2F&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=4th+Annual+Benchmark+Consumer+One-On-One+Conference&amp;index=3&amp;md5=144d79ad19a12a5290c8f4806d2c9941\" rel=\"nofollow\" shape=\"rect\">4th Annual Benchmark Consumer One-On-One Conference<\/a><\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Location<\/b>: New York Athletic Club<\/li>\n<li>\n<b>Date<\/b>: May 19, 2026<\/li>\n<li>\n<b>Format<\/b>: One-on-one meetings<\/li>\n<li>\n<b>Management<\/b>: Rob Fried, CEO, and Ozan Pamir, CFO<\/li>\n<\/ul><p>\nIf you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email <a  href=\"mailto:Niagen@KCSA.com\" rel=\"nofollow\" shape=\"rect\">Niagen@KCSA.com<\/a>.<\/p><p>\nFor additional information on Niagen Bioscience, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.niagenbioscience.com&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=www.niagenbioscience.com&amp;index=4&amp;md5=8a65117bcfa37b591891d5eb30af7b8f\" rel=\"nofollow\" shape=\"rect\">www.niagenbioscience.com<\/a>.<\/p><p>\n<b>About Niagen Bioscience:<\/b><\/p><p>\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=5&amp;md5=582dfdf444fae1887fd9f7a39d3ff925\" rel=\"nofollow\" shape=\"rect\">Niagen Bioscience, Inc.<\/a> (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience<b><sup>\u2122<\/sup><\/b> is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.<\/p><p>\nThe Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.<\/p><p>\nDistinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There\u2019s a better way to age.<\/p><p>\nAt the heart of its clinically proven product portfolio is Niagen\u00ae (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company\u2019s consumer supplement, Tru Niagen\u00ae, the number one NAD+ boosting oral supplement in the United States\u2020 (available at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.truniagen.com&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=www.truniagen.com&amp;index=6&amp;md5=158de4a8138d3ad8a2061c8d2b975d6d\" rel=\"nofollow\" shape=\"rect\">www.truniagen.com<\/a>), and Niagen\u2122 Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.niagenplus.com&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=www.niagenplus.com&amp;index=7&amp;md5=176c3d0c5a5b11a1c9faa7c721ff14e2\" rel=\"nofollow\" shape=\"rect\">www.niagenplus.com<\/a>). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.<\/p><p>\nNiagen Bioscience\u2019s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.niagenbioscience.com&amp;esheet=54531705&amp;newsitemid=20260508658207&amp;lan=en-US&amp;anchor=www.niagenbioscience.com&amp;index=8&amp;md5=bdcf6bf561915e786ce2aba36868ff8c\" rel=\"nofollow\" shape=\"rect\">www.niagenbioscience.com<\/a>, where copies of press releases, news, and financial information are regularly published.<\/p><p>\n<sup>\u2020<\/sup><i>Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 \u2013 Dec. 2025)<\/i><\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Niagen Bioscience Media Contact:<\/b><br\/>Kendall Knysch, Senior Director of Media Relations &amp; Partnerships\n<br\/>310.405.5227\n<br\/><a  href=\"mailto:kendall.knysch@niagenbio.com\" rel=\"nofollow\" shape=\"rect\">kendall.knysch@niagenbio.com<\/a><\/p><p>\n<b>Niagen Bioscience Investor Relations Contact:<\/b><br\/>Valter Pinto, Managing Director\n<br\/>KCSA Strategic Communications\n<br\/>212.896.1254\n<br\/><a  href=\"mailto:Niagen@kcsa.com\" rel=\"nofollow\" shape=\"rect\">Niagen@kcsa.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;$NAGE #Biotech&#8211;Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2911","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2911"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2911\/revisions"}],"predecessor-version":[{"id":2912,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/2911\/revisions\/2912"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}